Interferon-alpha, particularly in early-stage PV or ET, has demonstrated the ability to induce hematologic remission, reduce JAK2 V617F allele burden, and possibly alter the natural course of the disease. The gene discussed is JAK2; the disease is acquired polycythemia vera.